IPA: India's Pharma Industry to Benefit from Off-Patent Generics, an Industrial Info Market Brief

Indian pharmaceutical manufacturers, whose major revenue comes from the export of generic medicines, are likely to benefit substantially from the patent cliff. Indian generics account for 20% of global exports in terms of volume.

According to a report from Indian Pharmaceutical Alliance (IPA), off-patent branded molecules would open new opportunities for India's generics industry, as patents for molecules worth a cumulative global sale of more than $251 billion are expected to expire by 2024.

This may lead to massive capacity expansions in India via implementation of large-scale capital projects as well as plant upgrades. Industrial Info is tracking more than capital projects in India's pharmaceutical and biotech sector, with a total investment value of $7.27 billion. Click here for a list.